By Research Area
Hot products 
-
Mouse Anti-CCND2 Recombinant Antibody (DCS-3) (CBMAB-G1318-LY)
-
Mouse Anti-CAT Recombinant Antibody (724810) (CBMAB-C8431-LY)
-
Rabbit Anti-BRCA2 Recombinant Antibody (D9S6V) (CBMAB-CP0017-LY)
-
Mouse Anti-BMI1 Recombinant Antibody (CBYC-P026) (CBMAB-P0108-YC)
-
Mouse Anti-ADAM29 Recombinant Antibody (V2-179787) (CBMAB-A1149-YC)
-
Mouse Anti-AKT1 Recombinant Antibody (V2-180546) (CBMAB-A2070-YC)
-
Rabbit Anti-ALDOA Recombinant Antibody (D73H4) (CBMAB-A2314-YC)
-
Rat Anti-CD300A Recombinant Antibody (172224) (CBMAB-C0423-LY)
-
Mouse Anti-ADIPOR2 Recombinant Antibody (V2-179983) (CBMAB-A1369-YC)
-
Rabbit Anti-CCL5 Recombinant Antibody (R0437) (CBMAB-R0437-CN)
-
Mouse Anti-CD24 Recombinant Antibody (2Q1282) (CBMAB-C1624-CN)
-
Mouse Anti-GDF5 Recombinant Antibody (1F4) (CBMAB-G2740-LY)
-
Rat Anti-ADGRE4 Recombinant Antibody (V2-160163) (CBMAB-F0011-CQ)
-
Mouse Anti-8-oxoguanine Recombinant Antibody (V2-7697) (CBMAB-1869CQ)
-
Mouse Anti-FN1 Monoclonal Antibody (71) (CBMAB-1241CQ)
-
Mouse Anti-ADV Recombinant Antibody (V2-503423) (CBMAB-V208-1364-FY)
-
Mouse Anti-BBS2 Recombinant Antibody (CBYY-0253) (CBMAB-0254-YY)
-
Mouse Anti-APP Recombinant Antibody (5C2A1) (CBMAB-A3314-YC)
-
Mouse Anti-CDKL5 Recombinant Antibody (CBFYC-1629) (CBMAB-C1689-FY)
-
Mouse Anti-EPO Recombinant Antibody (CBFYR0196) (CBMAB-R0196-FY)
By Hallmark/Pathway
The progression from neoplastic transformation to metastatic dissemination is governed by the acquisition of specific biological capabilities—the hallmarks of cancer. These phenotypic alterations, ranging from sustained proliferative signaling to the evasion of immune destruction, are underpinned by profound dysregulation within intracellular kinase networks and transcriptional machinery. Contemporary research emphasizes the need to dissect these pathways not in isolation, but as integrated circuits that drive tumor heterogeneity and therapeutic resistance.
Targeting these mechanisms requires tools of exceptional specificity. Whether investigating the "angiogenic switch" mediated by hypoxic gradients or delineating the epithelial-mesenchymal transition (EMT) axis that facilitates invasion, the fidelity of molecular detection is paramount. Our portfolio is systematically organized to address these critical research nodes, offering validated antibodies and assays designed to interrogate cell cycle checkpoints, apoptotic thresholds, vascular remodeling, and the immunosuppressive tumor microenvironment with high-resolution precision.
Browse by Hallmark/Pathway
Select a pathway to explore targets, antibodies, and validation data.
Loading...
Compare
